CN
Oncology& Immunology

Oncology & Immunology

The Oncology & Immunology team works efficiently with partners to enable cancer drug discovery through our leading oncology and immuno-oncology capabilities. We provide a wide panel of in vivo tumor model systems including human cancer cell line-derived xenograft (CDX) models, murine syngeneic tumor models/humanized models, and patient-derived xenograft (PDX) models with in-depth genomic characterization. We have established a comprehensive immune profiling platform including TILs analysis, IHC and TCR repertoire to advance immune-oncology discovery. Our CRISPR screening can offer target validation services. The oncology & immunology team has extensive experience in IND-enabling studies for both FDA and CFDA filing, as either standalone or integrated drug discovery programs, plus clinical biomarker service to support clinical trials.

 

Capabilities at a Glance

  • 1,200+ tumor models
  • 1,000+ patient-derived xenograft (PDX) models
  • 191 cell line derived xenograft (CDX) models
  • 59 syngeneic models
  • 1,000+ human tumor cell lines
  • 100+ validated biomarkers

 

About the Team

  • 350+ scientists with operations in Shanghai, Suzhou and Nantong
  • Leaders with 15+ years gobal industry experience
  • ~70% PhD/MS, many with oversea training
  • AAALAC credited SPF animal facility
  • CAP certified clinical pathology and FACS lab
  • 30,000 IVC-cages

 

Comprehensive Platform and Services